SE7611379L - Antihypertensiva medel - Google Patents

Antihypertensiva medel

Info

Publication number
SE7611379L
SE7611379L SE7611379A SE7611379A SE7611379L SE 7611379 L SE7611379 L SE 7611379L SE 7611379 A SE7611379 A SE 7611379A SE 7611379 A SE7611379 A SE 7611379A SE 7611379 L SE7611379 L SE 7611379L
Authority
SE
Sweden
Prior art keywords
antihypertensive agents
amino
dimethoxyqui
nazoline
dimethoxyquinazoline
Prior art date
Application number
SE7611379A
Other languages
English (en)
Other versions
SE422685B (sv
Inventor
M Winn
J Kyncl
D A Dunnigan
P H Jones
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24492453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE7611379(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of SE7611379L publication Critical patent/SE7611379L/sv
Publication of SE422685B publication Critical patent/SE422685B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE7611379A 1975-10-14 1976-10-13 Forfarande for framstellning av 2-(4-(tetrahydro-2-furoyl)-piperazin)-4-amino-6,7-dimetoxikinazolin SE422685B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/621,980 US4026894A (en) 1975-10-14 1975-10-14 Antihypertensive agents

Publications (2)

Publication Number Publication Date
SE7611379L true SE7611379L (sv) 1977-04-15
SE422685B SE422685B (sv) 1982-03-22

Family

ID=24492453

Family Applications (2)

Application Number Title Priority Date Filing Date
SE7611379A SE422685B (sv) 1975-10-14 1976-10-13 Forfarande for framstellning av 2-(4-(tetrahydro-2-furoyl)-piperazin)-4-amino-6,7-dimetoxikinazolin
SE8008533A SE431208B (sv) 1975-10-14 1980-12-04 Forfarande for framstellning av 2-(4-(tetrahydropyran-2-karbonyl)piperazinyl)-4-amino-6,7-dimetoxikinazolin

Family Applications After (1)

Application Number Title Priority Date Filing Date
SE8008533A SE431208B (sv) 1975-10-14 1980-12-04 Forfarande for framstellning av 2-(4-(tetrahydropyran-2-karbonyl)piperazinyl)-4-amino-6,7-dimetoxikinazolin

Country Status (10)

Country Link
US (2) US4026894A (sv)
JP (1) JPS5248678A (sv)
AU (1) AU498925B2 (sv)
CA (1) CA1057754A (sv)
CH (1) CH602712A5 (sv)
DE (1) DE2646186A1 (sv)
FR (1) FR2327787A1 (sv)
GB (1) GB1517403A (sv)
MX (1) MX3620E (sv)
SE (2) SE422685B (sv)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1591490A (en) * 1977-08-04 1981-06-24 Abbott Lab 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride dihydrate
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
FR2421888A1 (fr) * 1978-02-06 1979-11-02 Synthelabo Amides d'alkylene-diamines et leur application en therapeutique
US4197301A (en) * 1978-10-16 1980-04-08 Allergan Pharmaceuticals, Inc. Topical ophthalmic use of Prazosin
US4287341A (en) * 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
DK121080A (da) * 1979-04-25 1980-10-26 Pfizer Fremgangsmaade til fremstilling af 2-piperazinoquinazolinderivater
EP0022481A1 (en) * 1979-06-21 1981-01-21 Mitsubishi Yuka Pharmaceutical Co., Ltd. 5,6-Alkylenepyrimidine derivatives, processes for preparing the same and pharmaceutical compositions
HU180708B (en) * 1979-10-11 1983-04-29 Chinoin Gyogyszer Es Vegyeszet Process for preparing new 1,2,4-oxadiazine derivatives
US4351940A (en) * 1980-03-03 1982-09-28 Pfizer Inc. Chloro- and alkoxy-substituted-2-chloro-4-aminodquinazolines
US4367335A (en) * 1981-08-03 1983-01-04 Mead Johnson & Company Thiazolidinylalkylene piperazine derivatives
DE3346675A1 (de) * 1983-12-23 1985-07-04 Beiersdorf Ag, 2000 Hamburg Substituierte 1-(4-amino-6,7-dialkoxy-chinazolinyl)-4- cyclohexenyl-derivate des piperazins und homopiperazins, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen und zwischenprodukte
FI79107C (sv) * 1984-06-25 1989-11-10 Orion Yhtymae Oy Förfarande för framställning av stabil -form av prazosinhydroklorid.
CA1307786C (en) * 1984-12-14 1992-09-22 Keiichi Yokoyama Quinazoline derivatives and antihypertensive preparations containing same as effective components
EP0237608B1 (de) * 1986-03-21 1992-01-29 HEUMANN PHARMA GMBH & CO Kristalline, wasserfreie Sigma -Form von 2-[4-(2-Furoyl-(2-piperazin)-1-yl]-4-amino-6,7-dimethoxychinazolinhydrochlorid und Verfahren zu ihrer Herstellung
YU70890A (en) * 1989-04-21 1992-05-28 Egyt Gyogyszervegyeszeti Gyar Process for obtaining quinazoline derivatives
JPH03286800A (ja) * 1990-04-03 1991-12-17 Gunze Ltd 衣類の折畳み装置
US5212176A (en) * 1990-06-29 1993-05-18 Abbott Laboratories R(+)-terazosin
IL101243A (en) * 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
CA2077252C (en) * 1992-08-31 2001-04-10 Khashayar Karimian Methods of making ureas and guanidines, and intermediates therefor
US5294615A (en) * 1993-04-29 1994-03-15 Abbott Laboratories Terazosin polymorph and pharmaceutical composition
US5412095A (en) * 1993-04-29 1995-05-02 Abbott Laboratories Terazosin monohydrochloride and processes and intermediate for its production
IT1270993B (it) * 1994-03-18 1997-05-26 Recordati Chem Pharm Derivati chinzolilamminici attivi come alfa-antagonisti
US5504207A (en) * 1994-10-18 1996-04-02 Abbott Laboratories Process and intermediate for the preparation of terazosin hydrochloride dihydrate
EP0853479A4 (en) * 1995-09-29 2001-04-11 Merck & Co Inc ALPHA 1b ADRENERGIC RECEPTOR ANTAGONISTS
US5587377A (en) * 1995-10-24 1996-12-24 Invamed, Inc. Terazosin crystalline polymorph and pharmaceutical compositions thereof
DE19546573A1 (de) * 1995-12-13 1997-06-19 Uetikon Chemie Gmbh Kristallines Polymorph von Terazosin-Hydrochlorid, sowie Verfahren zu seiner Herstellung
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
CA2173408C (en) * 1996-04-03 2001-09-04 K.S. Keshava Murthy Process for the manufacture of intermediates suitable to make doxazosin,terazosin, prazosin, tiodazosin and related antihypertensive medicines
US5952003A (en) * 1996-08-01 1999-09-14 Novartis Corporation Terazosin capsules
IT1286790B1 (it) * 1996-11-29 1998-07-17 Alfa Chem Ital Processo per la produzione della forma i del terazosin monocloridrato anidro
IT1286789B1 (it) * 1996-11-29 1998-07-17 Alfa Chem Ital Processo per la produzione della forma i del terazosin monocloridato anidro
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
US6248888B1 (en) * 1997-11-14 2001-06-19 Teva Pharmaceutical Industries Ltd. Process for the preparation of terazosin hydrochloride dihydrate
EP1891954A3 (en) 1998-09-30 2009-01-14 Takeda Pharmaceutical Company Limited Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
US20030060513A1 (en) * 2001-09-27 2003-03-27 Arneric Stephen P. Pharmaceutical composition
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
US20030229001A1 (en) * 2002-01-31 2003-12-11 Pfizer Inc. Treatment of male sexual dysfunction
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) * 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
CA2509605C (en) 2002-12-13 2010-10-05 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
PA8597401A1 (es) * 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
BRPI0414277A (pt) 2003-09-12 2006-11-07 Allergan Inc métodos e composições para o tratamento de dor e outras condições mediadas adrenérgicas alfa 2
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US20050267096A1 (en) * 2004-05-26 2005-12-01 Pfizer Inc New indazole and indolone derivatives and their use pharmaceuticals
US20050288270A1 (en) * 2004-05-27 2005-12-29 Pfizer Inc New aminopyridine derivatives and their use as pharmaceuticals
CA2500676A1 (en) * 2005-03-11 2006-09-11 Apotex Pharmachem Inc. Preparation of acid addition salts of amine bases by solid phase-gas phase reactions
JP2008533193A (ja) * 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
JP2008533192A (ja) * 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシンアンタゴニストとしての置換されたトリアゾール誘導体
US20060264442A1 (en) * 2005-05-18 2006-11-23 Allergan, Inc. Methods for the treatment of ocular and neurodegenerative conditions in a mammal
CA2618103A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
US20070086958A1 (en) * 2005-10-14 2007-04-19 Medafor, Incorporated Formation of medically useful gels comprising microporous particles and methods of use
US20070161791A1 (en) * 2006-01-09 2007-07-12 Narsimha Reddy Penthala Process for the preparation of terazosin hydrocloride dihydrate
CN101190890B (zh) * 2006-11-30 2011-04-27 江苏豪森药业股份有限公司 5-[(2r)-[2-[2-[2-(2,2,2-三氟乙氧基)苯氧基]乙基]氨基]丙基]-2-甲氧基苯磺酰胺
WO2009007984A2 (en) * 2007-07-11 2009-01-15 Hetero Drugs Limited An improved process for erlotinib hydrochloride
CN103739596A (zh) * 2013-12-10 2014-04-23 刘磊 用于心脑血管疾病的喹唑啉衍生物
US11224572B1 (en) 2020-08-17 2022-01-18 Novitium Pharma LLC Stable oral liquid composition of terazosin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US3669968A (en) * 1970-05-21 1972-06-13 Pfizer Trialkoxy quinazolines
JPS536156B2 (sv) * 1972-10-30 1978-03-04

Also Published As

Publication number Publication date
DE2646186A1 (de) 1977-04-28
SE431208B (sv) 1984-01-23
MX3620E (es) 1981-04-02
JPS5248678A (en) 1977-04-18
SE8008533L (sv) 1980-12-04
JPS5543474B2 (sv) 1980-11-06
US4112097A (en) 1978-09-05
DE2646186C2 (sv) 1987-10-29
FR2327787B1 (sv) 1980-10-10
US4026894A (en) 1977-05-31
FR2327787A1 (fr) 1977-05-13
GB1517403A (en) 1978-07-12
CA1057754A (en) 1979-07-03
AU498925B2 (en) 1979-03-29
CH602712A5 (sv) 1978-07-31
SE422685B (sv) 1982-03-22
AU1655776A (en) 1978-02-09

Similar Documents

Publication Publication Date Title
SE7611379L (sv) Antihypertensiva medel
NO952151D0 (no) Injiserbare, taxanderivat-baserte preparater
DK1124842T3 (da) Betulinsyrederivater anvendelige til behandling af neuroektodermale tumorer
TR199800436A2 (xx) Primidin t�revlerinin kanserin �nlenmesi i�in kullan�lmas�.
CY1109567T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν δροσπιρενονη
HUP9902121A2 (hu) Gonadotropin-leadó hormon antagonista hatású indolszármazékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
ATE47715T1 (de) Stabile salze von sam mit polyanionen.
YU149791A (sh) Mometason, furoat monohidrat i postupak za njegovo dobijanje
ES2108129T3 (es) Nuevos derivados de pirazina, su preparacion y empleo.
DE69706825D1 (de) Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
TR200000153T2 (tr) İl-5 inhibite eden 6-azaurasil türevleri.
ES460351A1 (es) Procedimiento para la preparacion de 2-bromo-6 - fluor-n-2- imidazolidinilidenbenzamina.
SE8501882D0 (sv) Pyridinderivat och framstellning derav
JPS5225772A (en) Preparation of molecular compound of allantoin and ornithine
SE8402199L (sv) Farmaceutiskt preparat innehallande co-dergocrin och en kalciumantagonist
ES456280A1 (es) Un procedimiento para la obtencion de alfa-2,5,9-trimetil- benzo(b)tieno(2,3-f)morfano.
NL190573C (nl) Farmaceutisch preparaat met diuretische, antihypertensieve en cardiale werking, alsmede 2,4,7-triamino-6-fenylpteridineverbindingen.
JPS525769A (en) Preparation of 3-substituted pyrolidine derivatives
MX12192A (es) Composicion farmaceutica para reducir o impedir las arritmias
KR890012651A (ko) 이뇨제 또는 항고혈압제 조성물
JPS5248677A (en) Preparation of pyrimidine derivatives
JPS5217482A (en) Preparation of quinazolinone derivatives
JPS53101535A (en) Deodorant comosition
JPS525782A (en) Preparation of 1-phthalazinone
JPS5248670A (en) Preparation of 2,5-disubstituted-pyridine derivatives

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 7611379-4

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 7611379-4

Format of ref document f/p: F